The study for clinical usefulness of the cross-linked N-telopeptide of type I collagen as a marker of bone metastasis from lung cancer
Not Applicable
Completed
- Conditions
- lung cancer, breast cancer
- Registration Number
- JPRN-UMIN000005553
- Lead Sponsor
- Osaka prefectural Medical Center for Respiratory and Allergic Diseases
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 200
Inclusion Criteria
Not provided
Exclusion Criteria
1:Patient who judged that research representative or allotment researcher is improper 2:Bisphosphonate administering patient 3:Metabolic bone disease patient 4:Kidney function deterioration patient
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1:Severrity of symptoms of bone metastasis in bone scintigraphy and comparative study of NTx 2-1:Utility examination of NTX in monitor of therapeutic gain after bone metastasis is diagnosed and bone metastasis progress level 2-2:Utility of bone metastasis index
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What is the role of cross-linked N-telopeptide of type I collagen (NTx) in detecting bone metastasis from lung cancer?
How does NTx compare to other biomarkers like CTX or PTH in predicting bone metastasis in non-small cell lung cancer patients?
What are the potential adverse events associated with NTx monitoring in lung cancer patients with bone metastases?
Are there combination therapies involving NTx biomarker assessment and standard treatments for lung cancer bone metastasis?
What is the clinical significance of NTx levels in monitoring treatment response for breast cancer patients with bone metastases?